Open AccessTrimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes
Author(s) -
Xinmin S. Li,
Slayman Obeid,
Zeneng Wang,
Benjamin Hazen,
Li Lin,
Yuping Wu,
Alex G Hurd,
Xiaodong Gu,
Alan Pratt,
Bruce S. Levison,
YoonMi Chung,
Steven E. Nissen,
W.H. Wilson Tang,
François Mach,
Lorenz Räber,
David Nanchen,
Christian M. Matter,
Thomas F. Lüscher,
Stanley L. Hazen
Publication year - 2019
Publication title -
european heart journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.336
H-Index - 293
eISSN - 1522-9645
pISSN - 0195-668X
DOI - 10.1093/eurheartj/ehz259
Subject(s) - medicine , mace , trimethylamine n oxide , hazard ratio , myocardial infarction , odds ratio , unstable angina , cohort , confidence interval , gastroenterology , cardiology , percutaneous coronary intervention , trimethylamine , biochemistry , chemistry
Trimethyllysine (TML) serves as a nutrient precursor of the gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) and is associated with incident cardiovascular (CV) events in stable subjects. We examined the relationship between plasma TML levels and incident CV events in patients presenting with acute coronary syndromes (ACS).